Table 2 Characteristics of the included studies for target AUC/MIC based on effectiveness
Study | Design of study | Country | Duration of study | Age of patients | Patient’s condition | Definition of AUC values | Target AUC/MIC breakpoint |
|---|---|---|---|---|---|---|---|
Zelenitsky 2013 [40] | Retrospective | Canada, America, Saudi Arabia | 1996–2005 | ≥18 Mean ± SD: 55.9 ± 16.7 | MRSA-associated septic shock | Values calculated (i) within the first 72 h of therapy based on the measured and extrapolated serum levels, and (ii) at steady-state using the daily dose divided by the population pharmacokinetic model derived vancomycin clearance | ≥ 451 |
Ghosh 2014 [22] | Retrospective | Australia | 2006–2012 | > 18 Median (range): 64.6 (22–95) | MRSA bacteremia | D/(CLcr × 0.79) + 15.4] × 0.06 | ≥ 398 |
Jung 2014 [41] | Retrospective | Korea | 2009–2012 | ≥18 Median (IQR): 69 (34–93) | MRSA bacteremia | Values estimated fitting vancomycin serum levels to a two-compartment volume clearance model using the maximum a posteriori probability Bayesian approach | ≥ 398.5 |
Song 2015 [23] | Prospective | Korea | 2005–2007 | ≥18 Median (IQR): 67 (53–75) | MRSA bacteremia | The total vancomycin dose in milligrams for 24 h over the vancomycin clearance | ≥ 392.7 |
Makmor-bakry 2019 [42] | Retrospective | Malaysia | N/A | ≥18 Mean ± SD: 59.2 ± 14.5 | MRSA bacteremia | Values estimated from the trough level and published vancomycin population PK values | ≥ 400 |